News
SNDX ▼ -17.6% - Syndax Pharmaceuticals, Inc.
SNDX ▼ -17.6% - Syndax Pharmaceuticals, Inc.
$SNDX - Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
12-OCT-2026 04:01 PM ET
Share this post
More filings for $SNDX
SNDX ▼ -0.7% - Syndax Pharmaceuticals, Inc.Oct 30, 2026SNDX ▼ -0.4% - Syndax Pharmaceuticals, Inc.Oct 30, 2026SNDX ▲ +0.1% - Syndax Pharmaceuticals, Inc.Oct 26, 2026SNDX ▲ +0.9% - Syndax Pharmaceuticals, Inc.Oct 15, 2026SNDX ▼ -3.4% - Syndax Pharmaceuticals, Inc.Oct 2, 2026SNDX ▼ -0.3% - Syndax Pharmaceuticals, Inc.Sep 1, 2026
View full $SNDX filing history →💬 Comments
Loading comments…
Leave a comment